Clinical features of the CN-AML patients harboring the CBFA2T3-GLIS2 fusion gene
| ID . | Age, years . | Gender . | WBC, × 109/L . | FAB . | BM blast, percentage at diagnosis . | Extramedullary involvement . | HSCT (type) . | CR after induction therapy . | Relapse (site) . | Disease-free duration (months) . | Survival duration (months) . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1* | 0.8 | M | 13.63 | M2 | 52 | No | Yes (MFD) | Yes | 46.7 | +48.0 | |
| 2* | 0.3 | F | 7.52 | M5A | 88 | No | Yes (AUTO) | Yes | 90.6 | +91.4 | |
| 3 | 1.4 | F | 65.08 | M0 | 98 | No | Yes (AUTO) | Yes | Yes (BM) | 9.3 | 13.0 |
| 4 | 12.7 | F | 22.8 | M1 | 61 | No | Yes (AUTO) | Yes | 70.1 | +74.5 | |
| 5 | 17.0 | F | 0.91 | M1 | 98 | No | Yes (AUTO) | Yes | Yes (BM + skin) | 38.7 | 50.4 |
| 6 | 13.3 | M | 7.52 | M5 | 90 | No | No | No | 2.6 | ||
| 7 | 0.9 | M | 7.53 | M5 | 60 | No | Yes (MUD) | Yes | Yes (BM) | 15.1 | 19.3 |
| 8 | 12.1 | M | 20.82 | M0 | 70 | No | Yes (AUTO) | Yes | Yes (BM) | 22.7 | 24 |
| 9 | 17.2 | M | 35.7 | M0 | 85 | No | No | No | 3.2 | ||
| 10 | 16.4 | F | 26.4 | M4 | 70 | No | Yes (AUTO) | Yes | Yes (BM) | 8.2 | 12.1 |
| 11 | 3.2 | F | 24.2 | M7 | 70 | No | Yes (MUD) | Yes | Yes (BM) | 12.2 | 24.7 |
| 12 | 4.0 | M | 12.79 | M7 | 74 | No | Yes (MUD) | Yes | Yes (BM) | 8.6 | 10.7 |
| 13 | 0.7 | M | 13.6 | M7 | 95 | Yes (CNS) | Yes (MUD) | No | 9.4 | ||
| 14 | 0.7 | F | 9.6 | M7 | 90 | No | Yes (MUD) | No | Yes (BM) | 21.1 | |
| 15 | 2.0 | F | 7.4 | M7 | 95 | No | Yes (MFD) | Yes | 109.2 | +111.8 | |
| 16 | 1.4 | F | 128.6 | M7 | 50 | No | No | No | 2.1 | ||
| 17* | 0.5 | F | 13.25 | M7 | 90 | No | No | Yes | Yes (BM + CNS) | 3.2 | 5.7 |
| 18 | 3.0 | F | 13.63 | M7 | 40 | No | Yes (MUD) | Yes | 37.2 | +45.2 | |
| 19 | 1.6 | F | 115 | M7 | 90 | No | Yes (MFD) | Yes | Yes (BM) | 17.7 | 24.7 |
| 20 | 1.9 | F | 56.5 | M7 | 30 | No | Yes (MFD) | Yes | 13.5 | +15.6 |
| ID . | Age, years . | Gender . | WBC, × 109/L . | FAB . | BM blast, percentage at diagnosis . | Extramedullary involvement . | HSCT (type) . | CR after induction therapy . | Relapse (site) . | Disease-free duration (months) . | Survival duration (months) . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1* | 0.8 | M | 13.63 | M2 | 52 | No | Yes (MFD) | Yes | 46.7 | +48.0 | |
| 2* | 0.3 | F | 7.52 | M5A | 88 | No | Yes (AUTO) | Yes | 90.6 | +91.4 | |
| 3 | 1.4 | F | 65.08 | M0 | 98 | No | Yes (AUTO) | Yes | Yes (BM) | 9.3 | 13.0 |
| 4 | 12.7 | F | 22.8 | M1 | 61 | No | Yes (AUTO) | Yes | 70.1 | +74.5 | |
| 5 | 17.0 | F | 0.91 | M1 | 98 | No | Yes (AUTO) | Yes | Yes (BM + skin) | 38.7 | 50.4 |
| 6 | 13.3 | M | 7.52 | M5 | 90 | No | No | No | 2.6 | ||
| 7 | 0.9 | M | 7.53 | M5 | 60 | No | Yes (MUD) | Yes | Yes (BM) | 15.1 | 19.3 |
| 8 | 12.1 | M | 20.82 | M0 | 70 | No | Yes (AUTO) | Yes | Yes (BM) | 22.7 | 24 |
| 9 | 17.2 | M | 35.7 | M0 | 85 | No | No | No | 3.2 | ||
| 10 | 16.4 | F | 26.4 | M4 | 70 | No | Yes (AUTO) | Yes | Yes (BM) | 8.2 | 12.1 |
| 11 | 3.2 | F | 24.2 | M7 | 70 | No | Yes (MUD) | Yes | Yes (BM) | 12.2 | 24.7 |
| 12 | 4.0 | M | 12.79 | M7 | 74 | No | Yes (MUD) | Yes | Yes (BM) | 8.6 | 10.7 |
| 13 | 0.7 | M | 13.6 | M7 | 95 | Yes (CNS) | Yes (MUD) | No | 9.4 | ||
| 14 | 0.7 | F | 9.6 | M7 | 90 | No | Yes (MUD) | No | Yes (BM) | 21.1 | |
| 15 | 2.0 | F | 7.4 | M7 | 95 | No | Yes (MFD) | Yes | 109.2 | +111.8 | |
| 16 | 1.4 | F | 128.6 | M7 | 50 | No | No | No | 2.1 | ||
| 17* | 0.5 | F | 13.25 | M7 | 90 | No | No | Yes | Yes (BM + CNS) | 3.2 | 5.7 |
| 18 | 3.0 | F | 13.63 | M7 | 40 | No | Yes (MUD) | Yes | 37.2 | +45.2 | |
| 19 | 1.6 | F | 115 | M7 | 90 | No | Yes (MFD) | Yes | Yes (BM) | 17.7 | 24.7 |
| 20 | 1.9 | F | 56.5 | M7 | 30 | No | Yes (MFD) | Yes | 13.5 | +15.6 |
+, patients alive and in CR; AUTO, autologous; CNS, central nervous system; CR, complete remission; HSCT, hematopoietic stem cell transplantation; MFD, matched family donor; MUD, matched unrelated donor; WBC, white blood cells.
Patients identified in the RNA-seq screening.